[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fAGmQ-ozos2w9SoT42hrrGmU4t48wFQ3B38RaOSvaLMY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":49,"rows":56},"Istituti Clinici Scientifici Maugeri SpA",[4],112,false,49,0,18605,5,106,[14,17,20,22,24,26,29,32],{"name":15,"count":16},"Breast Cancer",12,{"name":18,"count":19},"COPD",6,{"name":21,"count":11},"Parkinson Disease",{"name":23,"count":11},"Stroke",{"name":25,"count":11},"Asthma",{"name":27,"count":28},"Healthy Volunteers",4,{"name":30,"count":31},"Amyotrophic Lateral Sclerosis",3,{"name":33,"count":31},"Rehabilitation",[35,40,45],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05842551","Prismatic Lenses and tDCS in Neglect","2026-07-15","Prismatic adaptation and electric stimulation",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05852223","Pembrolizumab in High-risk Thyroid Cancer","2026-11","Pembrolizumab",{"nctId":46,"briefTitle":47,"date":48,"intervention":44},"NCT05925491","Pembrolizumab in Locally Advanced Sinonasal Carcinoma","2026-12",[50,51,52,53,54,55],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[57,91,110,128,146,168,199,217,235,261],{"intervention":44,"totalTrials":58,"cells":59},2,{"EARLY_PHASE1":60,"PHASE1":62,"PHASE2":64,"PHASE3":85,"PHASE4":87,"NA":89},{"trials":61,"activeCount":9},[],{"trials":63,"activeCount":9},[],{"trials":65,"activeCount":58,"soonestReadout":43},[66,78],{"nctId":46,"briefTitle":47,"status":67,"phases":68,"primaryCompletion":48,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":74},"RECRUITING",[52],"2027-12","2024-12-24",28,[73],"Sinonasal Undifferentiated Carcinoma",[44,75,76,77],"Cisplatin","Docetaxel","Carboplatin",{"nctId":41,"briefTitle":42,"status":67,"phases":79,"primaryCompletion":43,"completion":43,"start":80,"enrollment":81,"conditions":82,"interventions":84},[52],"2024-12-20",25,[83],"Differentiated Thyroid Cancer",[44],{"trials":86,"activeCount":9},[],{"trials":88,"activeCount":9},[],{"trials":90,"activeCount":9},[],{"intervention":75,"totalTrials":92,"cells":93},1,{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":104,"PHASE4":106,"NA":108},{"trials":95,"activeCount":9},[],{"trials":97,"activeCount":9},[],{"trials":99,"activeCount":92,"soonestReadout":48},[100],{"nctId":46,"briefTitle":47,"status":67,"phases":101,"primaryCompletion":48,"completion":69,"start":70,"enrollment":71,"conditions":102,"interventions":103},[52],[73],[44,75,76,77],{"trials":105,"activeCount":9},[],{"trials":107,"activeCount":9},[],{"trials":109,"activeCount":9},[],{"intervention":76,"totalTrials":92,"cells":111},{"EARLY_PHASE1":112,"PHASE1":114,"PHASE2":116,"PHASE3":122,"PHASE4":124,"NA":126},{"trials":113,"activeCount":9},[],{"trials":115,"activeCount":9},[],{"trials":117,"activeCount":92,"soonestReadout":48},[118],{"nctId":46,"briefTitle":47,"status":67,"phases":119,"primaryCompletion":48,"completion":69,"start":70,"enrollment":71,"conditions":120,"interventions":121},[52],[73],[44,75,76,77],{"trials":123,"activeCount":9},[],{"trials":125,"activeCount":9},[],{"trials":127,"activeCount":9},[],{"intervention":77,"totalTrials":92,"cells":129},{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":140,"PHASE4":142,"NA":144},{"trials":131,"activeCount":9},[],{"trials":133,"activeCount":9},[],{"trials":135,"activeCount":92,"soonestReadout":48},[136],{"nctId":46,"briefTitle":47,"status":67,"phases":137,"primaryCompletion":48,"completion":69,"start":70,"enrollment":71,"conditions":138,"interventions":139},[52],[73],[44,75,76,77],{"trials":141,"activeCount":9},[],{"trials":143,"activeCount":9},[],{"trials":145,"activeCount":9},[],{"intervention":39,"totalTrials":92,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":158},{"trials":149,"activeCount":9},[],{"trials":151,"activeCount":9},[],{"trials":153,"activeCount":9},[],{"trials":155,"activeCount":9},[],{"trials":157,"activeCount":9},[],{"trials":159,"activeCount":92,"soonestReadout":38},[160],{"nctId":36,"briefTitle":37,"status":67,"phases":161,"primaryCompletion":38,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":167},[55],"2026-12-31","2023-03-07",30,[166],"Stroke, Ischemic",[39],{"intervention":169,"totalTrials":92,"cells":170},"Palbociclib",{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":181},{"trials":172,"activeCount":9},[],{"trials":174,"activeCount":9},[],{"trials":176,"activeCount":9},[],{"trials":178,"activeCount":9},[],{"trials":180,"activeCount":9},[],{"trials":182,"activeCount":9},[183],{"nctId":184,"briefTitle":185,"status":186,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":196},"NCT04524728","Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy","COMPLETED",[],"2019-04","2020-06","2016-12",191,[193,194,195],"Breast","Neoplasm Malignant","Female",[169,197,198],"Letrozole 2.5mg","Fulvestrant",{"intervention":197,"totalTrials":92,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":211},{"trials":202,"activeCount":9},[],{"trials":204,"activeCount":9},[],{"trials":206,"activeCount":9},[],{"trials":208,"activeCount":9},[],{"trials":210,"activeCount":9},[],{"trials":212,"activeCount":9},[213],{"nctId":184,"briefTitle":185,"status":186,"phases":214,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":215,"interventions":216},[],[193,194,195],[169,197,198],{"intervention":198,"totalTrials":92,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":229},{"trials":220,"activeCount":9},[],{"trials":222,"activeCount":9},[],{"trials":224,"activeCount":9},[],{"trials":226,"activeCount":9},[],{"trials":228,"activeCount":9},[],{"trials":230,"activeCount":9},[231],{"nctId":184,"briefTitle":185,"status":186,"phases":232,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":233,"interventions":234},[],[193,194,195],[169,197,198],{"intervention":236,"totalTrials":92,"cells":237},"Mepolizumab",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":248},{"trials":239,"activeCount":9},[],{"trials":241,"activeCount":9},[],{"trials":243,"activeCount":9},[],{"trials":245,"activeCount":9},[],{"trials":247,"activeCount":9},[],{"trials":249,"activeCount":9},[250],{"nctId":251,"briefTitle":252,"status":186,"phases":253,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":260},"NCT05063981","Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma",[],"2023-09-29","2025-09-02","2021-11-25",15,[259],"Severe Eosinophilic Asthma",[236],{"intervention":262,"totalTrials":92,"cells":263},"Antiepileptic Drug",{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":270,"PHASE4":272,"NA":274},{"trials":265,"activeCount":9},[],{"trials":267,"activeCount":9},[],{"trials":269,"activeCount":9},[],{"trials":271,"activeCount":9},[],{"trials":273,"activeCount":9},[],{"trials":275,"activeCount":9},[276],{"nctId":277,"briefTitle":278,"status":186,"phases":279,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":287},"NCT05823168","Seizures and Traumatic Brain Injury Rehabilitation",[],"2022-12-31","2025-01-14","2021-01-01",84,[285,286],"Seizures","Traumatic Brain Injury",[262]]